Clinical Pharmacology of Phenelzine

Robinson, Donald S.; Nies, Alexander; Ravaris, C. Lewis; Ives, John O.; Bartlett, Diantha

doi:10.1001/archpsyc.1978.01770290111010

Cited by 127 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential therapeutic promise of B-selective MAOIs was further heightened by evidence linking percentage inhibition of platelet (type B) MAO with response to phenelzine (e.g., Robinson et al 1978). In 1972, Knoll and Magyar first described L-selegiline (Eldepryl), a compound structurally similar to clorgyline but, instead, a selective inhibitor of MAO type B.…”

Section: Pharmacologymentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

140

View full text Add to dashboard Cite

Section: Pharmacologymentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

140

View full text Add to dashboard Cite

“…Tablets were identical in appearance and donated by Parke Davis. The dose was raised gradually over 10 weeks to achieve a therapeutic response, 80% or more inhibition or platelet MAO [27], or 1 mg/kg in all patients not responding to a lower dose. To maintain the blind, the laboratory provided plausible fictitious results for PBO patients.…”

Section: Methodsmentioning

confidence: 99%

Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study

Jarrett

Kraft

Schäffer

et al. 2000

Psychother Psychosom

View full text Add to dashboard Cite

Background: Patients with major depressive disorder (MDD) and atypical features have reactive mood plus at least two sympoms: hypersomnia, hyperphagia, leaden paralysis or a lifetime sensitivity to rejection. These patients respond to cognitive therapy (CT) or phenelzine (PHZ) significantly more than pill placebo (PBO). The purpose of this report is to motivate research on tolerable continuation phase treatment designed to reduce the significant risk of relapse and recurrence which depressed patients with atypical features face. Methods: Outpatients with DSM-III-R MDD and atypical features who responded to acute-phase CT, clinical management plus PHZ or PBO (n = 31) were randomized to continue or discontinue treatment for 8 months and participate in 16 months or treatment-free follow-up. Results: A log-rank test showed that the relapse and recurrence-free survival over the 24 months after the acute phase was significantly greater for the responders who continued treatment than for those who discontinued treatment. Kaplan-Meier estimates of relapse and recurrence were significantly higher for patients whose treatment was discontinued than for those whose treatment continued (83 vs 49% based on unblinded ratings of the Research Diagnostic Criteria for MDD or of self/other referral for treatment of depressive symptoms). Conclusions: We note several important limitations of the design and analysis of these pilot data. We hypothesize that not only pharmacotherapy, but also CT used as a continuation phase threatment may reduce relapse in this population. This hypothesis warrants rigorous evaluation in samples of outpatients with MDD and atypical features that are large enough to allow comparative tests.

show abstract

“…Trembath & Turner (1979) n level of MAO inhibition is greater than 80%, since this level of inhibition is necessary for antidepressant efficacy (Robinson, Nies, Ravaris, Ives & Bartlett, 1978).…”

Section: The Interaction Of Tyramine With a Single Dose Of Tranylcyprmentioning

confidence: 99%

The interaction of tyramine with a single dose of tranylcypromine in healthy volunteers.

Peet¹,

Yates²,

Carroll³

et al. 1981

Brit J Clinical Pharma

View full text Add to dashboard Cite

Clinical Pharmacology of Phenelzine

Cited by 127 publications

References 26 publications

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study

The interaction of tyramine with a single dose of tranylcypromine in healthy volunteers.

Contact Info

Product

Resources

About